A. Ravelli et al., FREQUENCY OF RELAPSE AFTER DISCONTINUATION OF METHOTREXATE THERAPY FOR CLINICAL REMISSION IN JUVENILE RHEUMATOID-ARTHRITIS, Journal of rheumatology, 22(8), 1995, pp. 1574-1576
Objective. To investigate the outcome of children with juvenile rheuma
toid arthritis (JRA) who discontinued taking methotrexate (MTX) therap
y after the achievement of clinical remission. Methods. We conducted a
retrospective review of the clinical course of all consecutive patien
ts with JRA treated with MTX at our department. Results. Seventeen of
the 30 patients who responded to treatment entered clinical remission
6 to 30 mo after beginning MTX therapy. All patients were discontinued
from MTX within 2 to 5 mo. Five patients relapsed within 9 mo, wherea
s 12 patients had sustained remission for 12 mo or longer. Four of 5 c
hildren with extended pauciarticular JRA relapsed early after MTX disc
ontinuation. These patients were less responsive to a further cycle of
MTX, acid 3 showed progression of radiographic joint lesions. Conclus
ion. These findings suggest that MTX should be continued in patients w
ith extended pauciarticular JRA even after the achievement of clinical
remission.